Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2004-09-13
2008-11-11
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S091200, C536S023500, C536S024310, C530S350000, C530S395000
Reexamination Certificate
active
07449292
ABSTRACT:
Methods and compositions for the detection, diagnosis, and prevention of cardiac conditions are provided. Polymorphisms of β1-adrenergic receptor are provided. The Gly389 β1-adrenergic receptor variants are not as responsive to treatment β blockers such as carvedilol, metoprolol or bisoprol. Thus, genotyping β1-adrenergic receptor polymorphisms is useful for predicting relative responsiveness to treatment with beta blockers. The Gly389 polymorphism also may be used, alone or in conjunction with other adrenergic receptor polymorphisms, to predict relative risk of developing cardiovascular diseases such as heart failure or to predict relative survival rate in patients with heart failure or other cardiovascular diseases. Also provided are transgenic mice and transgenic cells expressing the β1-adrenergic receptor polymorphisms, and their use in identifying therapeutic agents.
REFERENCES:
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5002867 (1991-03-01), Macevicz
patent: 5130238 (1992-07-01), Malek et al.
patent: 5169766 (1992-12-01), Schuster et al.
patent: 5202231 (1993-04-01), Drmanac et al.
patent: 5302509 (1994-04-01), Cheeseman
patent: 5679524 (1997-10-01), Nikiforov et al.
patent: 6365618 (2002-04-01), Swartz
patent: 2002/0187491 (2002-12-01), Johnson
patent: 2003/0113725 (2003-06-01), Small et al.
patent: 2003/0143608 (2003-07-01), Filigheddu et al.
patent: 329822 (1994-06-01), None
patent: WO88/10315 (1988-12-01), None
patent: WO89/06700 (1989-07-01), None
patent: WO89/10414 (1989-11-01), None
patent: WO90/01069 (1990-02-01), None
patent: WO90/09455 (1990-08-01), None
patent: WO91/02087 (1991-02-01), None
patent: WO92/15712 (1992-09-01), None
patent: WO94/03630 (1994-02-01), None
patent: WO95/17676 (1995-06-01), None
patent: WO 01/11039 (2001-02-01), None
Perez et al. Nature Medicine. Sep. 14, 2003, 9: 1300-1305.
Small et al. Methods in Enzymology. 2002. 343: 459-475.
Liu et al. Clinical Pharmacology & Therapeutics. 2003. 74:372-379.
Mason, Moore, Green and Liggett, “A Gain-of-Function Polymorphism in a G-protein Coupling Domain of the Human β1Adrenergic Receptor,”J. Biol. Chem.274 (18), pp. 12670-12674 (1999).
Small, Wagoner, Levin, Kardia and Liggett, “Synergistic Polymorphisos of β1and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure,”New Engl. J. of Med.347:1135-1142 (Oct. 10, 2002).
De Boer, R. A., et al., “Polypharmacy in Chronic Heart Failure: Practical Issues Regarding the Use of Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers and Other Drugs,” European Society of Cardiology, European Heart Journal Supplements, Apr. 2002, pp. D111-D116, vol. 4, Supplement D.
Kass, D. A., “β-Receptor Polymorphisms: Heart Failure's Crystal Ball,” Nature Medicine, Oct. 2003, pp. 1260-1262, vol. 9, No. 10.
Maqbool, A., et al., “Common Polymorphisms of β1-Adrenoceptor: Identification and Rapid Screening Assay,” The Lancet, Mar. 13, 1000, pp. 897, vol. 353, No. 9156, Lancet Limited, London, GB.
Perez, J. M., et al., “β1-Adrenergic Receptor Polymorphisms Confer Differential Function and Predisposition to Heart Failure,” Nature Medicine, pp. 1300-1305, vol. 9, No. 10.
Sofowora G. G., “A Common β1-Adrenergic Receptor Ploymorphism (Arg389Gly) Affects Blood Pressure Response to β1Blockade,” Clinical Pharmacology & Therapeutics, Apr. 2003, pp. 366-371, vol. 73, No. 4, Mosby-Year Book St. Louis, MO.
Tesson, F., et al., “Characterization of a Unique Genetic Variant in the β1-Adrenoceptor Gene and Evaluation of its Role in Idiopathic Dilated Cardiomyopathy,” Journal of Molecular and Cellular Cardiology, May 1999, pp. 1025-1032, vol. 31.
Wagoner, L. E., et al., “Polymorphisms of the β1-Adrenergic Receptor Predict Exercise Capacity in Heart Failure,” American Heart Journal, Nov. 2002, pp. 840-846, vol. 144, No. 5.
Givertz, M.M. Underlying causes and survival in patients with heart failure. N.Engl. J. Med.342, 1 120-1 122 (2000).
van Campen, L.C., Visser, F.C. & Visser, C.A. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature.J. Cardiovasc. Pharmacol.Suppl 1, S31-S35 (1998).
Franz, W.-M., Müller, O.J. & Katus, H.A. Cardiomyopathies: from genetics to the prospect of treatment.Lancet358, 1627-1637 (2001).
Engelhardt, S., Hein, L., Wiesmann, F. & Lohse, M.J. Progressive hypertrophy and heart failure in beta 1 -adrenergic receptor transgenic mice.Proc. Natl. Acad. Sci. U.S.A.96, 7059-7064 (1999).
Liggett, S.B. β-adrenergic receptors in the failing heart: the good, the bad, and the unknown.J. Clin. Invest.107, 947-948 (2001).
Mason, D.A., Moore, J.D., Green, S.A. & Liggett, S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human β1adrenergic receptor.J. Biol. Chem.274, 12670-12674 (1999).
Moore, J.D., mason, D.A., Green, S.A., Hsu, J. & Liggett, S.B. Racial differences in the frequencies of cardiac β1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C.Hum. Mutat. Mutation and Polymorphism Report #56 Online. Citation also in printHum. Mutat.14, 271-271 (1999).
Palczewski, K. et al. Crystal structure of rhodopsin: A G protein-coupled receptor.Science289, 739-745 (2000).
Wagoner, L.E. et al. Polymorphisms of the β1-adrenergic receptor predict exercise capacity in heart failure.Am. Heart J144, 840-846 (2002).
Bengtsson, K. et al. Polymorphism in the β1-adrenergic receptor gene and hypertension.Circ.104, 187-190 (2001).
D'Angelo, D.D. et al., Transgenic Gαq overexpression induces cardiac contractile failure in mice.Proc. Natl. Acad. Sci. U. S. A.94, 8121-8126 (1997).
Liggett, S.B. et al. Early and delayed consequences of β1-adrenergic receptor overexpression in mouse hearts.Circ.101, 1707-1714 (2000).
Bristow, M.R. et al. Decreased catecholamine sensitivity and β1-adrenergic-receptor density in failing human hearts. N.Engl, J. Med.307, 205-211 (1982).
Bristow, M.R., Hershberger, R.E., Port, J.D., Minobe, W. & Rasmussen, R. β1- and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.Mol. Pharmacol.35, 295-303 (1988).
Dunigan, C.D. Hoang, Q., Curran, P.K. & Fishman, P.H. Complexity of agonist- and cyclic AMP-mediated downregulation of the human β1-adrenergic receptor: role of internalization, degradation, and mRNA destabilization.Biochm.41, 8019-8030 (2002).
Dorn, G.W.I., Tepe, N.M., Wu, G., Yatani, A. & Liggett, S.B. Mechanisms of impaired β adrenergic receptor signaling in Gαq-mediated cardiac hypertrophy and ventricular dysfunction.Mol. Pharmacol.57, 278-287 (2000).
Bohm, M. et al. Desensitization of adenylate cyclase and increase of Gi alpha in cardiac hypertrophy due to acquired hypertension.Hypertension20, 103-112 (1992).
Ungerer, M., Bohm, M., Elce, J.S., Erdrnann, E. & Lohse, M.J. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart,Circ.87, 454-463 (1993).
Bohm, M. et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy,Circ.82, 1249-1265 (1990).
Eschenhagen, T. et al. Increased messenger RNA level of the inhibitory G protein α subunit Giα-2in human end-stage heart failure.Circ. Res.70, 688-696 (1992).
Packer, M. et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.Circ.106, 2194-2199 (2002).
Bristow, M.R. et al. β1-and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor downregulation in heart failure.Circ. Res
Liggett Stephen Bryant
Wagoner Lynne Elizabeth
Fenwick & West LLP
Myers Carla
University of Cincinnati
LandOfFree
Methods for predicting relative efficacy of a beta blocker... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for predicting relative efficacy of a beta blocker..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for predicting relative efficacy of a beta blocker... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034714